Playback speed
10 seconds
ESMO GI 2024 Insights: 1L Unresectable HCC - Outcomes by Comorbidities With STRIDE (Durvalumab & Tremelimumab Regimen) in the HIMALAYA Study
By
Insights from 2024 ESMO GI Annual Meeting
FEATURING
Lorenza Rimassa
By
Insights from 2024 ESMO GI Annual Meeting
FEATURING
Lorenza Rimassa
145 views
July 5, 2024
Comments 0
Login to view comments.
Click here to Login